Hello and welcome back.

It’s officially spring – the season of growth and renewal 🌸 It’s the perfect time for self-reflection and intention setting. As you take on some spring cleaning, remember to take some time to declutter your mind too 😌

Here’s what’s in store for you in today’s issue:

🍄 Why the UK is becoming a psychedelic hotspot

🍄 Growing peyote sustainably

🍄 Natural vs. synthetic psilocybin

🍄 Ketamine + Parkinson’s meds

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

A doctor’s view on group psychedelic therapy & microdosing

In this episode of the Daily Mushroom podcast, we have Dr. Pam Kryskow, a psychedelic researcher, medical doctor, and the medical lead for ketamine-assisted therapy for the Roots to Thrive program. Pam shares the benefits of psychedelic therapy in group settings and how her hiking “trips” helped her cope with daily trauma experienced in her previous job as a firefighter.

inspirational banner

Why the UK is becoming a psychedelic hotspot

The UK is on a mission to create a world-leading clinical research ecosystem that’s more efficient and effective than ever before – and many psychedelic companies are taking advantage of the regulatory changes.

To reach this goal, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) now allows “real world data” (data collected from patients and healthcare systems outside of clinical trials) to aid in the drug approval process

This may bring psychedelic therapies to market much faster not only in the UK, but also in Australia, Canada, Singapore and Switzerland, as the MHRA joined a coalition with these countries called the Access Consortium.

Additionally, the UK may reschedule psilocybin to Schedule 2, reducing barriers to clinical research.

Just yesterday, COMPASS Pathways (CMPS) announced a strategic partnership to launch a major psychedelic research center in the UK.

Other companies to keep an eye on that may benefit from these changes include Albert Labs (ABRT), Awakn Life Sciences (AWKN), Small Pharma (DMT), Beckley Psytech, Eleusis.

Peyote, but ✨sustainable✨

Peyote has the longest documented use of any psychedelic, yet we don’t see many companies researching its properties.

That’s because the psychedelic cactus is endangered – the 13-year growth cycle can’t keep up with the rate of harvesting.

Lophos Pharmaceuticals is developing a sustainable cultivation technique that could reduce the long growth cycle to just 3 years, preserving the species and accelerating research.

The CEO of Lophos says that peyote could help treat obesity, addiction, anxiety, and depression, with a strong potential for microdosing. 


Peyote is a cactus containing the psychedelic compound mescaline. It’s been used in Indigenous healing ceremonies for centuries.

Therapeutic banner

Is psilocybin the only beneficial compound in magic mushrooms?

If synthetic psilocybin is cheaper to produce, why are many psychedelic companies sticking with the natural route?

Some believe that consumers would rather take a naturally grown mushroom than something formulated in a lab. 

Other researchers, like those at Filament Health (FH), think the other unknown compounds in the mushroom could provide additional benefits that complement psilocybin. 

This theory, called “the entourage effect”, is popular in the cannabis industry too.

Filament Health is committed to all-natural psilocybin and has developed a way to produce it at a low cost. They just received a second patent for the extraction and standardization of natural psilocybin.

Ketamine + Parkinson’s meds

The most common Parkinson’s medication, Levodopa, causes involuntary muscle movements in most patients who take it long-term.

PharmaTher (PHRM) found that a low dose of ketamine reduces these muscle spams in 100% of Parkinson’s patients — but it’s unclear by how much or for how long 🤔

However, a separate study from 2016 found that low doses of ketamine reduced this side effect for up to one month and also eased depression.

PharmaTher is confident that the results will pave the way for a Phase 3 trial. 

business banner

Kernel is recruiting participants for a study that will examine brain activity on a low dose of ketamine, which is sponsored by Cybin (CYBN)Learn how you can participate here.

Mind Cure Health (MCUR) and Core One Labs (COOL) appear to be running out of money as they look for strategic takeover opportunities 😬

Biomind Labs (BMND) is launching a commercial clinical trial on its proprietary mescaline-based formulation. The drug targets inflammation, which the company believes is the root cause of many forms of depression.

Novamind (NM) is piloting a group therapy model for psychedelic sessions and integration sessions in groups of 4-10 people. Both drop-in sessions and multi-week programs will be offered.

Tryp Therapeutics (TRYP) began enrolling patients for a Phase 2 trial on psilocybin for binge eating. The company is using non-proprietary synthetic psilocybin to generate data quickly while developing a proprietary formulation

legal banner

Third Michigan city decriminalizes psychedelics 🎉

Hazel Park became the third city in Michigan to decriminalize a range of psychedelics, following Ann Arbor and Detroit. 

Activists continue to push for statewide ballot initiative to legalize the possession, cultivation, and sharing of natural psychedelics and set up a system for therapeutic use.

Connecticut psilocybin + MDMA bill advances

A bill that would create psychedelic treatment centers for psilocybin and MDMA therapy was approved by a legislative committee, advancing to floor consideration.

Treatments would be focused on veterans, first responders, healthcare workers, and those from underserved communities with life-threatening mental illness.

Follow our Instagram @dailymushroom.co for more trippy inspiration and fun graphics like this one!